HDAC6 and lobular neoplasia: In lupus nephritis(LN), the researchers treated NZB/W lupus mice with a selective histone deacetylase 6 (HDAC6) inhibitor for 4 weeks and showed that HDAC6 inhibition decreased B-cell activating signaling pathways, resulting in a significant reduction in LN symptoms (52).